Immunitybio Inc (IBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -583,852 | -350,438 | -254,796 | -116,583 | -417,320 |
| Depreciation Amortization | 61,794 | 49,210 | 33,187 | 16,217 | 35,860 |
| Accounts payable and accrued liabilities | -6,476 | -3,599 | -869 | 668 | 8,000 |
| Other Working Capital | 3,828 | 29,726 | 36,729 | 27,670 | -8,001 |
| Other Operating Activity | 157,949 | 23,615 | 21,666 | -12,282 | 43,952 |
| Operating Cash Flow | $-366,757 | $-251,486 | $-164,083 | $-84,310 | $-337,509 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -10,358 | -10,192 | -236 | -158 | -500 |
| PPE Investments | -30,584 | -22,629 | -16,954 | -8,428 | -78,162 |
| Purchase Of Investment | N/A | N/A | N/A | N/A | -1,000 |
| Sale Of Investment | 10,472 | 102 | 102 | 102 | 128,188 |
| Purchase Sale Intangibles | N/A | N/A | N/A | N/A | -21,229 |
| Other Investing Activity | 0 | 0 | 0 | 0 | -21,229 |
| Investing Cash Flow | $-30,470 | $-32,719 | $-17,088 | $-8,484 | $27,297 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 258,700 | 258,700 | 59,700 | 29,850 | 174,125 |
| Debt Repayment | -77 | -57 | -38 | -19 | -58 |
| Common Stock Issued | 110,397 | 101,040 | 61,055 | 47,414 | 60,501 |
| Other Financing Activity | 189,321 | -1,881 | -417 | -357 | -955 |
| Financing Cash Flow | $558,341 | $357,802 | $120,300 | $76,888 | $233,613 |
| Exchange Rate Effect | -292 | -265 | -264 | -254 | 284 |
| Beginning Cash Position | 104,965 | 104,965 | 104,965 | 104,965 | 181,280 |
| End Cash Position | 265,787 | 178,297 | 43,830 | 88,805 | 104,965 |
| Net Cash Flow | $160,822 | $73,332 | $-61,135 | $-16,160 | $-76,315 |
| Free Cash Flow | |||||
| Operating Cash Flow | -366,757 | -251,486 | -164,083 | -84,310 | -337,509 |
| Capital Expenditure | -30,584 | -22,629 | -16,954 | -8,428 | -78,162 |
| Free Cash Flow | -397,341 | -274,115 | -181,037 | -92,738 | -415,671 |